Iterion Presents New Data on First-in-Class TBL1 Inhibitor Tegavivint, Targeting Wnt-Driven Cancers at AACR Annual Meeting

HOUSTON, April 13, 2026 /PRNewswire/ — Iterion Therapeutics announced that two abstracts featuring its first-in-class TBL1 inhibitor, tegavivint, will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Each will highlight the company’s approach to targeting the Wnt/β-catenin pathway, one of the most frequently dysregulated signaling programs in cancer.

The release as fetched from its publisher. iteriontherapeutics.com ↗